Amendment to the Claims:

Please AMEND the claims as follows:

- 1. (CURRENTLY AMENDED) A process for the preparation of transplant acceptance inducing cells of monocytic origin characterised characterized in that
 - a) monocytes are isolated from blood;
- b) the monocytes are multiplied in a suitable culture medium which contains the cellular growth factor M-CSF;
- c) the monocytes are cultivated simultaneously with or following step b) in a culture medium containing γ -IFN; and
- d) the transplant acceptance inducing cells formed in step c) are obtained by separating the cells from the culture medium.
- 2. (CURRENTLY AMENDED) A process according to claim 1 characterised characterized in that the monocytes are of human origin.
- 3. (CURRENTLY AMENDED) A process according to claims 1 or 2 characterised characterized in that the monocytes are isolated form the blood in such a manner that next to the monocytes also lymphocytes are present in an amount of at least 10% by reference to the total cell number in the isolate.
- 4. (CURRENTLY AMENDED) A process according to claims 1 to 3, characterised characterized in that the transplant acceptance inducing cells formed in step c) or obtained in step d) are selected by binding to the antibody produced by the hybridoma cell line DSM ACC2542.
- 5. (CURRENTLY AMENDED) A process according to claims 1 to 4, eharacterised characterized in that among the transplant acceptance inducing cells formed in step c) or obtained in step d) of claim 1 or obtained in the selection step according to claim 4 those cells are selected which co-express the antigens CD3 and CD14 on their cell surface.

- 6. (CURRENTLY AMENDED) A process according to claims 1 to 5, characterised characterized in that the M-CSF concentration in the culture medium is 1 to 20 μg/l.
- 7. (CURRENTLY AMENDED) A process according to claims 1 to 6, eharacterised characterized in that, subsequent to step b) the monocytes are cultivated for 24 to 72 hours in a culture medium containing γ -IFN, the cultivation in the presence of γ -IFN beginning 3 to 6 days after the beginning of cultivation step b).
- 8. (CURRENTLY AMENDED) A process according to claim 7, characterised characterized in that the γ-IFN concentration in the culture medium is 0.1 to 20 ng/ml.
- 9. (CURRENTLY AMENDED) A process according to claims 1 to 8 characterised characterized in that the total cultivation period in steps b) and c) is 4 to 8 days.
- 10. (CURRENTLY AMENDED) A process according to claims 1 to 8 characterised characterized in that subsequent to step d) of claim 1, or subsequent to the selection steps according to claims 4 and 5, the cells are suspended in a suitable cell culture medium or in a PBS or NaCl solution.
- 11. (CURRENTLY AMENDED) A process according to claims 1 to 10 characterised characterized in that the cells are suspended in a freezing medium and are subsequently deep frozen.
- 12. (CURRENTLY AMENDED) A process according to claim 11 characterised characterized in that the freezing medium comprises fetal calf serum (FCS) or human AB serum and DMSO.

13. (CURRENTLY AMENDED) Transplant acceptance inducing cells of monocytic origin obtainable by any of the processes according to claims 1 to 12 characterised in that they co-express the antigens CD3 and CD14 on their cell surface.

14. (CANCELED)

- 15. (CURRENTLY AMENDED) Transplant acceptance inducing cells according to claims 13 or 14 characterised characterized in that they are of human origin.
- 16. (CURRENTLY AMENDED) Cell preparation containing the transplant acceptance inducing cells according to claims 13 to or 15 in a suitable medium.
- 17. (CURRENTLY AMENDED) Pharmaceutical composition containing transplant inducing cells of monocytic origin characterized in that they co-express the antigens CD3 and CD14 on their cell surface.
- 18. (CURRENTLY AMENDED) Pharmaceutical composition containing the transplant acceptance inducing cells according to claims 13 to or 15 or the cell preparation according to claim 16.
- 19. (CURRENTLY AMENDED) Use of the transplant acceptance inducing cells according to claims 13 to or 15 or the cell preparation according to claim 16 for manufacturing a pharmaceutical composition for the suppression of transplant rejection reactions.
- 20. (CURRENTLY AMENDED) The use of transplant acceptance inducing cells according to claims 13 to or 15 or the cell preparation of claim 16 for in *vitro* generating and/or propagating regulatory T-lymphocytes.

- 21. (ORIGINAL) The use according to claim 20, wherein the regulatory T-lymphocytes co-express the antigens CD4 and CD25 on their cell surface.
- 22. (CURRENTLY AMENDED) A process for the generation and/or propagation of regulatory T-lymphocytes, eharacterised characterized in that
- a) transplant acceptance inducing cells according to claims 13 to or 15 or a cell preparation according to claim 16 are co-cultivated with a T-lymphocyte preparation, and
 - b) the regulatory T-lymphocytes are optionally obtained from the culture medium.
- 23. (CURRENTLY AMENDED) A process according to claim 22, characterised characterized in that the regulatory T-lymphocytes co-express the antigens CD4 and CD25 on their cell surface.
- 24. (CURRENTLY AMENDED) A process according to claims 22 or 23, eharacterised characterized in the regulatory T-lymphocytes are obtained from the culture medium by FACS sorting.
 - 25. (CANCELED)
 - 26. (ORIGINAL) Hybridoma cell line DSM ACC2542.
 - 27. (ORIGINAL) Antibodies produced by the hybridoma cell line DSM ACC2542.
- 28. (ORIGINAL) The use of the antibody according to claim 22 for the detection and/or selection of transplant acceptance inducing cells.